SINPHAR (1734) reported revenue of NT$295.9 million for Oct 2026, +8.2% year on year and +16.3% from the previous month. Revenue for Jan–Oct 2026 was NT$2.84 billion (+2.7% year on year).
In Oct 2026, it ranked No. 33 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$295.9 million | +8.2% | +16.3% |
| Sep 2026 | NT$254.4 million | -22.5% | -18.2% |
| Aug 2026 | NT$311 million | +21.6% | +9.8% |
| Jul 2026 | NT$283.4 million | -2.9% | +1.7% |
| Jun 2026 | NT$278.6 million | +3.8% | -7.4% |
| May 2026 | NT$300.8 million | +10.3% | +3.2% |
| Apr 2026 | NT$291.5 million | +7.6% | -8.1% |
| Mar 2026 | NT$317.2 million | +5.1% | +61.6% |
| Feb 2026 | NT$196.3 million | -17.4% | -37.2% |
| Jan 2026 | NT$312.8 million | +17.4% | -3.0% |
| Dec 2025 | NT$322.5 million | +10.7% | +14.6% |
| Nov 2025 | NT$281.3 million | +3.2% | +2.9% |
| Oct 2025 | NT$273.5 million | -5.5% | -16.7% |
| Sep 2025 | NT$328.5 million | +56.7% | +28.4% |
| Aug 2025 | NT$255.8 million | -8.8% | -12.3% |
| Jul 2025 | NT$291.7 million | +11.7% | +8.6% |
| Jun 2025 | NT$268.5 million | -0.3% | -1.5% |
| May 2025 | NT$272.6 million | +6.1% | +0.6% |
| Apr 2025 | NT$271 million | +12.3% | -10.2% |
| Mar 2025 | NT$301.8 million | +13.0% | +27.1% |
| Feb 2025 | NT$237.5 million | +14.7% | -10.8% |
| Jan 2025 | NT$266.3 million | -12.3% | -8.6% |
| Dec 2024 | NT$291.3 million | +18.0% | +6.9% |
| Nov 2024 | NT$272.6 million | +3.7% | -5.8% |
| Oct 2024 | NT$289.3 million | +21.4% | +38.0% |
Jan–Oct 2026 cumulative: NT$2.84 billion (+2.7% YoY)
Other Biotech & Medical companies
Compare with peers: SINPHAR vs PEC / SINPHAR vs Lotus Pharm / SINPHAR vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16